Review

rabbit anti human pad2 antibody (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech rabbit anti human pad2 antibody

Effect of AMF30a on in vitro proliferation of human corneal endothelial cells (hCECs). AMF30a (5µM, <t>PAD2</t> inhibitor, Cayman, Ann Arbor, Michigan) was applied for 48 h. ( A ) hCECs were identified using immunofluorescence staining of ZO1 and CD166. ( B - C ) Cell area of hCECs were evaluated using cell morphological pictures. Scale bar = 100 μm. ( D and E ) Cell proliferation was measured using CCK-8 cell viability assay and BrdU incorporation assay. ( F ) Cytotoxicity was evaluated using LDH cytotoxicity assay (1.002 ± 0.047 vs. 0.925 ± 0.018). ( G - I ) Cell cycle analysis was assessed using PI staining. (J and K) Wound healing assay was performed using the measurement of scratched ares. Scale bar = 500 μm. ( L and N ) Intracellular oxidative stress levels were measured using DCF-DA assay. Scale bar = 50 μm. * p < 0.05, ** p < 0.01 and **** p < 0.0001.

Rabbit Anti Human Pad2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+pad2+antibody/pmc12317985-133-54-59?v=Proteintech
Average 94 stars, based on 70 article reviews

rabbit anti human pad2 antibody - by Bioz Stars, 2026-07

94/100 stars

Images

1) Product Images from "AMF30a promotes survival and function of human corneal endothelial cells by regulating TGF-β/ROCK/HIPPO pathway"

Article Title: AMF30a promotes survival and function of human corneal endothelial cells by regulating TGF-β/ROCK/HIPPO pathway

Journal: Scientific Reports

doi: 10.1038/s41598-025-13656-2

Effect of AMF30a on in vitro proliferation of human corneal endothelial cells (hCECs). AMF30a (5µM, PAD2 inhibitor, Cayman, Ann Arbor, Michigan) was applied for 48 h. ( A ) hCECs were identified using immunofluorescence staining of ZO1 and CD166. ( B - C ) Cell area of hCECs were evaluated using cell morphological pictures. Scale bar = 100 μm. ( D and E ) Cell proliferation was measured using CCK-8 cell viability assay and BrdU incorporation assay. ( F ) Cytotoxicity was evaluated using LDH cytotoxicity assay (1.002 ± 0.047 vs. 0.925 ± 0.018). ( G - I ) Cell cycle analysis was assessed using PI staining. (J and K) Wound healing assay was performed using the measurement of scratched ares. Scale bar = 500 μm. ( L and N ) Intracellular oxidative stress levels were measured using DCF-DA assay. Scale bar = 50 μm. * p < 0.05, ** p < 0.01 and **** p < 0.0001.

Figure Legend Snippet: Effect of AMF30a on in vitro proliferation of human corneal endothelial cells (hCECs). AMF30a (5µM, PAD2 inhibitor, Cayman, Ann Arbor, Michigan) was applied for 48 h. ( A ) hCECs were identified using immunofluorescence staining of ZO1 and CD166. ( B - C ) Cell area of hCECs were evaluated using cell morphological pictures. Scale bar = 100 μm. ( D and E ) Cell proliferation was measured using CCK-8 cell viability assay and BrdU incorporation assay. ( F ) Cytotoxicity was evaluated using LDH cytotoxicity assay (1.002 ± 0.047 vs. 0.925 ± 0.018). ( G - I ) Cell cycle analysis was assessed using PI staining. (J and K) Wound healing assay was performed using the measurement of scratched ares. Scale bar = 500 μm. ( L and N ) Intracellular oxidative stress levels were measured using DCF-DA assay. Scale bar = 50 μm. * p < 0.05, ** p < 0.01 and **** p < 0.0001.

Techniques Used: In Vitro, Immunofluorescence, Staining, CCK-8 Assay, Viability Assay, BrdU Incorporation Assay, LDH Cytotoxicity Assay, Cell Cycle Assay, Wound Healing Assay

Effect of cytokine on human corneal endothelial cells. ( A ) Immunofluorescence staining of PAD2 shows the distribution of PAD2. Scale bar = 100 μm. ( B and C ) Western blot of PAD2 was used to evaluate the PAD2 levels. ( D and E ) ATF4 levels were evaluated using western blot. ( F ) Immunofluorescence staining of peptidyl-citrulline shows the intensity and distribution of peptidyl-citrulline. Scale bar = 100 μm. * p < 0.05.

Figure Legend Snippet: Effect of cytokine on human corneal endothelial cells. ( A ) Immunofluorescence staining of PAD2 shows the distribution of PAD2. Scale bar = 100 μm. ( B and C ) Western blot of PAD2 was used to evaluate the PAD2 levels. ( D and E ) ATF4 levels were evaluated using western blot. ( F ) Immunofluorescence staining of peptidyl-citrulline shows the intensity and distribution of peptidyl-citrulline. Scale bar = 100 μm. * p < 0.05.

Techniques Used: Immunofluorescence, Staining, Western Blot

Figure Legend Snippet: Schematic diagram summarizing PAD2-mediated signaling in hCECs.

Techniques Used:

Image Search Results

Journal: Scientific Reports

Article Title: AMF30a promotes survival and function of human corneal endothelial cells by regulating TGF-β/ROCK/HIPPO pathway

doi: 10.1038/s41598-025-13656-2

Figure Lengend Snippet: Effect of AMF30a on in vitro proliferation of human corneal endothelial cells (hCECs). AMF30a (5µM, PAD2 inhibitor, Cayman, Ann Arbor, Michigan) was applied for 48 h. ( A ) hCECs were identified using immunofluorescence staining of ZO1 and CD166. ( B - C ) Cell area of hCECs were evaluated using cell morphological pictures. Scale bar = 100 μm. ( D and E ) Cell proliferation was measured using CCK-8 cell viability assay and BrdU incorporation assay. ( F ) Cytotoxicity was evaluated using LDH cytotoxicity assay (1.002 ± 0.047 vs. 0.925 ± 0.018). ( G - I ) Cell cycle analysis was assessed using PI staining. (J and K) Wound healing assay was performed using the measurement of scratched ares. Scale bar = 500 μm. ( L and N ) Intracellular oxidative stress levels were measured using DCF-DA assay. Scale bar = 50 μm. * p < 0.05, ** p < 0.01 and **** p < 0.0001.

Article Snippet: Primary antibodies were as follows: rabbit anti-human CD166 antibody (ab109215, Abcam, 1∶500 dilution), rabbit anti-human ZO-1 antibody (sc-10804, Santa Cruz, 1∶500 dilution), mouse anti-human ERK1/2 antibody (sc-514032, Santa Cruz, 1∶500 dilution); mouse anti-human pERK1/2 antibody (sc-136521, Santa Cruz, 1∶500 dilution); mouse anti-human YAP antibody (sc-376830, 1∶500 dilution); rabbit anti-pYAP antibody (PA5-17481, Invitrogen, 1∶500 dilution); rabbit anti-human PAD2 antibody (12110-1-AP, Proteintech, 1∶500 dilution); mouse anti-ATF4 antibody (sc-390063, 1∶500 dilution); mouse anti-human ROCK1 antibody (sc-17794, 1∶500 dilution); mouse anti-ROCK2 antibody (sc-398519, 1∶500 dilution); or rabbit anti-GAPDH antibody (LF-PA0212, Abfrontier, 1∶5000 dilution).

Techniques: In Vitro, Immunofluorescence, Staining, CCK-8 Assay, Viability Assay, BrdU Incorporation Assay, LDH Cytotoxicity Assay, Cell Cycle Assay, Wound Healing Assay

Journal: Scientific Reports

Article Title: AMF30a promotes survival and function of human corneal endothelial cells by regulating TGF-β/ROCK/HIPPO pathway

doi: 10.1038/s41598-025-13656-2

Figure Lengend Snippet: Effect of cytokine on human corneal endothelial cells. ( A ) Immunofluorescence staining of PAD2 shows the distribution of PAD2. Scale bar = 100 μm. ( B and C ) Western blot of PAD2 was used to evaluate the PAD2 levels. ( D and E ) ATF4 levels were evaluated using western blot. ( F ) Immunofluorescence staining of peptidyl-citrulline shows the intensity and distribution of peptidyl-citrulline. Scale bar = 100 μm. * p < 0.05.

Techniques: Immunofluorescence, Staining, Western Blot

Journal: Scientific Reports

Article Title: AMF30a promotes survival and function of human corneal endothelial cells by regulating TGF-β/ROCK/HIPPO pathway

doi: 10.1038/s41598-025-13656-2

Figure Lengend Snippet: Schematic diagram summarizing PAD2-mediated signaling in hCECs.

Techniques:

mRNA expression of protein arginine deiminase 2 and 4 in patients with inflammatory bowel diseases. mRNA was isolated from the ileal and colonic mucosa of patients with ulcerative colitis (UC; active disease, n = 20; remitted disease, n = 20) and Crohn’s disease (CD; active disease, n = 10; remitted disease, n = 10). Non-tumorous portions of the colonic mucosa in patients with colon adenoma served as healthy colonic mucosa (HC, n = 4). qRT-PCR analysis of the mRNA expression levels of protein arginine deiminase (PAD)2 and PAD4. Each dot represents the value for each patient. (A) Data are presented as the mean ± SE. ** p <0.01, N.S.; not significant. (B) Correlation between PAD2 and PAD4 mRNA expression in patients with UC and CD. P values and correlation coefficient ( r ) values, as determined by Pearson’s correlation coefficient, are shown.

Journal: Journal of Clinical Biochemistry and Nutrition

Article Title: Reciprocal regulation of protein arginine deiminase 2 and 4 expression in the colonic mucosa of ulcerative colitis

doi: 10.3164/jcbn.23-77

Figure Lengend Snippet: mRNA expression of protein arginine deiminase 2 and 4 in patients with inflammatory bowel diseases. mRNA was isolated from the ileal and colonic mucosa of patients with ulcerative colitis (UC; active disease, n = 20; remitted disease, n = 20) and Crohn’s disease (CD; active disease, n = 10; remitted disease, n = 10). Non-tumorous portions of the colonic mucosa in patients with colon adenoma served as healthy colonic mucosa (HC, n = 4). qRT-PCR analysis of the mRNA expression levels of protein arginine deiminase (PAD)2 and PAD4. Each dot represents the value for each patient. (A) Data are presented as the mean ± SE. ** p <0.01, N.S.; not significant. (B) Correlation between PAD2 and PAD4 mRNA expression in patients with UC and CD. P values and correlation coefficient ( r ) values, as determined by Pearson’s correlation coefficient, are shown.

Article Snippet: PAD2 and PAD4 expression was visualized using the DAKO EnVision+ System (DAKO JAPAN, Tokyo, Japan), as previously described, with rabbit human anti-PAD2 antibody (Proteintech, Rosemont, IL) and anti-PAD4 antibody (GeneTex, Irvine, CA). ( )

Techniques: Expressing, Isolation, Quantitative RT-PCR

Correlation between the mRNA expression of protein arginine deiminase 4 ( PAD4 ) and cytokines in patients with ulcerative colitis (UC). mRNA was isolated from the colonic mucosa of patients with UC. (A) Correlation between the mRNA expression of PAD4 and IFN-α4 , IFN-β , IL12/23p40 , C-X-C motif chemokine ligand 8 ( CXCL8 ), CXCL10 , TNF receptor-associated factor 3 ( TRAF3 ), interferon regulatory factor 3 ( IRF3 ), IRF7 , IL-6 , and TNF -α. (B) Correlation between the mRNA expression of PAD2 and IFN-α4 , IFN-β , CXCL8 , CXCL10 , IL-6 , and TNF -α. Each dot represents the value for each patient. P values and correlation coefficient ( r ) values, as determined by Pearson’s correlation coefficient, are shown.

Journal: Journal of Clinical Biochemistry and Nutrition

Article Title: Reciprocal regulation of protein arginine deiminase 2 and 4 expression in the colonic mucosa of ulcerative colitis

doi: 10.3164/jcbn.23-77

Figure Lengend Snippet: Correlation between the mRNA expression of protein arginine deiminase 4 ( PAD4 ) and cytokines in patients with ulcerative colitis (UC). mRNA was isolated from the colonic mucosa of patients with UC. (A) Correlation between the mRNA expression of PAD4 and IFN-α4 , IFN-β , IL12/23p40 , C-X-C motif chemokine ligand 8 ( CXCL8 ), CXCL10 , TNF receptor-associated factor 3 ( TRAF3 ), interferon regulatory factor 3 ( IRF3 ), IRF7 , IL-6 , and TNF -α. (B) Correlation between the mRNA expression of PAD2 and IFN-α4 , IFN-β , CXCL8 , CXCL10 , IL-6 , and TNF -α. Each dot represents the value for each patient. P values and correlation coefficient ( r ) values, as determined by Pearson’s correlation coefficient, are shown.

Techniques: Expressing, Isolation

Correlation between the mRNA expression of protein arginine deiminase 4 ( PAD4 ) and cytokines in patients with Crohn’s disease (CD). mRNA was isolated from the ileal and colonic mucosa of patients with CD. (A) Correlation between the mRNA expression of PAD4 and IFN-α4 , IFN-β , IL12/23p40 , C-X-C motif chemokine ligand 8 ( CXCL8 ), CXCL10 , TNF receptor-associated factor 3 ( TRAF3 ), interferon regulatory factor 3 ( IRF3 ), IRF7 , IL-6 , and TNF-α . (B) Correlation between the mRNA expression of PAD2 and IFN-α4 , IFN-β , CXCL8 , CXCL10 , IL-6 , and TNF-α . Each dot represents the value for each patient. P values and correlation coefficient ( r ) values, as determined by Pearson’s correlation coefficient, are shown.

Journal: Journal of Clinical Biochemistry and Nutrition

Article Title: Reciprocal regulation of protein arginine deiminase 2 and 4 expression in the colonic mucosa of ulcerative colitis

doi: 10.3164/jcbn.23-77

Figure Lengend Snippet: Correlation between the mRNA expression of protein arginine deiminase 4 ( PAD4 ) and cytokines in patients with Crohn’s disease (CD). mRNA was isolated from the ileal and colonic mucosa of patients with CD. (A) Correlation between the mRNA expression of PAD4 and IFN-α4 , IFN-β , IL12/23p40 , C-X-C motif chemokine ligand 8 ( CXCL8 ), CXCL10 , TNF receptor-associated factor 3 ( TRAF3 ), interferon regulatory factor 3 ( IRF3 ), IRF7 , IL-6 , and TNF-α . (B) Correlation between the mRNA expression of PAD2 and IFN-α4 , IFN-β , CXCL8 , CXCL10 , IL-6 , and TNF-α . Each dot represents the value for each patient. P values and correlation coefficient ( r ) values, as determined by Pearson’s correlation coefficient, are shown.

Techniques: Expressing, Isolation

Journal: BMC Cancer

Article Title: BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway

doi: 10.1186/s12885-018-4323-8

Figure Lengend Snippet: Primers used in the study

Article Snippet: The rabbit anti-human PAD2 and PAD4 antibodies were obtained from Proteintech (12110–1-AP; Rosemont, IL) and Sigma-Aldrich (P4749; St. Louis, MO), respectively.

Techniques:

Expression of PAD2 and PAD4 in non-malignant and tumoral canine and feline mammary cell lines. a Expression levels of the genes PAD2 and PAD4 in canine and feline normal and tumoral mammary cell lines as determined by qRT-PCR. b Protein expression in whole cell lysates subjected to SDS-PAGE and immunoblot analyses probed with PAD2 or PAD4 antibodies. β-actin was included as a loading control. Representative Western blots and quantifications are shown. Quantification is represented as the fold change of PAD2/4 band density over β-actin band density. c Protein expression in cells probed with either PAD2 or PAD4 antibodies and subjected to flow cytometry analyses. d Protein expression in whole cell lysates subjected to SDS-PAGE and immunoblot analyses probed with anti-modified citrulline antibodies. β-actin was included as a loading control. Representative Western blots and quantifications are shown. Quantification is represented as the fold change of modified-citrulline band density over β-actin band density. * P < 0.05, n = 3. Data are presented as mean ± standard deviation

Journal: BMC Cancer

Article Title: BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway

doi: 10.1186/s12885-018-4323-8

Figure Lengend Snippet: Expression of PAD2 and PAD4 in non-malignant and tumoral canine and feline mammary cell lines. a Expression levels of the genes PAD2 and PAD4 in canine and feline normal and tumoral mammary cell lines as determined by qRT-PCR. b Protein expression in whole cell lysates subjected to SDS-PAGE and immunoblot analyses probed with PAD2 or PAD4 antibodies. β-actin was included as a loading control. Representative Western blots and quantifications are shown. Quantification is represented as the fold change of PAD2/4 band density over β-actin band density. c Protein expression in cells probed with either PAD2 or PAD4 antibodies and subjected to flow cytometry analyses. d Protein expression in whole cell lysates subjected to SDS-PAGE and immunoblot analyses probed with anti-modified citrulline antibodies. β-actin was included as a loading control. Representative Western blots and quantifications are shown. Quantification is represented as the fold change of modified-citrulline band density over β-actin band density. * P < 0.05, n = 3. Data are presented as mean ± standard deviation

Article Snippet: The rabbit anti-human PAD2 and PAD4 antibodies were obtained from Proteintech (12110–1-AP; Rosemont, IL) and Sigma-Aldrich (P4749; St. Louis, MO), respectively.

Techniques: Expressing, Quantitative RT-PCR, SDS Page, Western Blot, Control, Flow Cytometry, Modification, Standard Deviation

Cellular localization of PAD2 and PAD4 in non-malignant and tumoral canine and feline mammary cell lines. Protein localization in cells probed with PAD2 or PAD4 antibodies and subjected to immunofluorescence. Representative fluorescence pictures ( a ) and quantifications, using Image J Software, ( b ) are shown. ** P < 0.01, n = 3. Data are presented as mean ± standard deviation

Journal: BMC Cancer

Article Title: BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway

doi: 10.1186/s12885-018-4323-8

Figure Lengend Snippet: Cellular localization of PAD2 and PAD4 in non-malignant and tumoral canine and feline mammary cell lines. Protein localization in cells probed with PAD2 or PAD4 antibodies and subjected to immunofluorescence. Representative fluorescence pictures ( a ) and quantifications, using Image J Software, ( b ) are shown. ** P < 0.01, n = 3. Data are presented as mean ± standard deviation

Article Snippet: The rabbit anti-human PAD2 and PAD4 antibodies were obtained from Proteintech (12110–1-AP; Rosemont, IL) and Sigma-Aldrich (P4749; St. Louis, MO), respectively.

Techniques: Immunofluorescence, Fluorescence, Software, Standard Deviation

Review

Structured Review

Images

1) Product Images from "AMF30a promotes survival and function of human corneal endothelial cells by regulating TGF-β/ROCK/HIPPO pathway"

Similar Products

Image Search Results